Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes.
Autophagy of Mitochondria: A Promising Therapeutic Target for Neurodegenerative Disease.
Predicting Breakdown of the Blood-Brain Barrier in Multiple Sclerosis without Contrast Agents.
Neurological perspectives on voltage-gated sodium channels.
Interleukin-10 Gene-transfected Mature Dendritic Cells Suppress Murine Experimental Autoimmune Optic Neuritis.
Multiple sclerosis guideline production takes off.
A novel model of demyelination and remyelination in a GFP-transgenic zebrafish.
High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Unraveling the Hygiene Hypothesis of helminthes and autoimmunity: origins, pathophysiology, and clinical applications.
Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.
How microglia kill neurons.
Design and development of an ethnically-diverse imaging informatics-based eFolder system for multiple sclerosis patients.
Schwann Cell Expressed Nogo-B Modulates Axonal Branching of Adult Sensory Neurons Through the Nogo-B Receptor NgBR.
Olfactory bulb and olfactory sulcus depths are associated with disease duration and attack frequency in multiple sclerosis patients.
Sequential activation of microglia and astrocyte cytokine expression precedes increased iba-1 or GFAP immunoreactivity following systemic immune challenge.
Clinical improvement precedes lesion size regression in a severe case of acute disseminated encephalomyelitis.
The radial diffusivity and magnetization transfer pool size ratio are sensitive markers for demyelination in a rat model of type III multiple sclerosis (MS) lesions.
Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks.
Association of innate immune activation with latent Epstein-Barr virus in active MS lesions.
Visual Evoked Potential and Magnetic Resonance Imaging are More Effective Markers of Multiple Sclerosis Progression than Laser Polarimetry with Variable Corneal Compensation.
How reliable is the classification of cognitive impairment across different criteria in early and late stages of multiple sclerosis?
A rare case of Balo concentric sclerosis showing unusual clinical improvement and response with oral prednisolone.
Electrodiagnostic evaluation of peripheral nervous system changes in patients with multiple sclerosis.
Longitudinally extensive varicella-zoster virus myelitis in a multiple sclerosis patient.
Neutrophils Amplify Autoimmune Central Nervous System Infiltrates by Maturing Local APCs.
Pages
« first
‹ previous
…
457
458
459
460
461
462
463
464
465
…
next ›
last »